AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31205681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild adverse events after manual therapy in men
Number of subjects: 771
Study 31205681 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate adverse events after manual therapy
Number of subjects: 771
Study 31205681 — intervention group
Group type: COMPARATOR
Intervention: No adverse events after manual therapy
Number of subjects: 771
Study 28044449 — intervention group
Group type: EXPERIMENTAL
Intervention: Curves Complete 90‐day Challenge (CC, n = 29)
Number of subjects: 133
Study 28044449 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers Points Plus (WW, n = 29)
Number of subjects: 133
Study 28044449 — intervention group
Group type: EXPERIMENTAL
Intervention: Jenny Craig At Home (JC, n = 27)
Number of subjects: 133
Study 28044449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrisystem Advance Select (NS, n = 28)
Number of subjects: 133
Study 28044449 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 133
Study 26990279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐CBT (6 sessions)
Number of subjects: 47
Study 26990279 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 47
Study 23937421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 8075
Study 23937421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 8075
Study 23937421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8075
Study 23937421 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 8075
Study 23534319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 70
Study 23534319 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 70
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use behaviors (including methamphetamine and heroin use)
Number of subjects: 3285
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/ethnicity (NH black, Hispanic, other/mixed)
Number of subjects: 3285
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual practices (males who only had sex with males)
Number of subjects: 3285
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting methamphetamine alone or with heroin
Number of subjects: 3285
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent means of obtaining income
Number of subjects: 3285
Study 19559543 — intervention group
Group type: EXPERIMENTAL
Intervention: History of exchanging sex for money/drugs
Number of subjects: 3285
Study 17430984 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 22
Study 17430984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16429184 — intervention group
Group type: COMPARATOR
Intervention: Control group (teeth with custom cast post and core)
Number of subjects: 50
Study 16429184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (teeth without remaining coronal structure)
Number of subjects: 50
Study 16429184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (teeth with 1 mm of remaining coronal structure)
Number of subjects: 50
Study 16429184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (teeth with 2 mm of remaining coronal structure)
Number of subjects: 50
Study 16429184 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (teeth with 3 mm of remaining coronal structure)
Number of subjects: 50
Study 11867507 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of isoflavones per day
Number of subjects: 34
Study 11867507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10468094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive therapy
Number of subjects: 0
Study 10468094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1352246 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 5 mg
Number of subjects: 6
Study 1352246 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg
Number of subjects: 6
Study 1352246 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (5-30 mg per day)
Number of subjects: 6
Study 1352246 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 6709431 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol aerosol 0.1% inhalation
Number of subjects: 10
Study 6709431 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol placebo
Number of subjects: 10
Study 30527750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment group
Number of subjects: 412
Study 30037035 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 836
Study 27277368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management with education
Number of subjects: 80
Study 27277368 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological management only
Number of subjects: 80
Study 25703908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt
Number of subjects: 81
Study 25703908 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg IM morphine
Number of subjects: 81
Study 23625867 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized heparin and protamine (HMS group, n=29)
Number of subjects: 60
Study 23625867 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (ACT group, n=24)
Number of subjects: 60
Study 20505152 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus AE-941
Number of subjects: 379
Study 20505152 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy plus placebo
Number of subjects: 379
Study 18539869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen alternated with ibuprofen
Number of subjects: 38
Study 18539869 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 38
Study 16377643 — intervention group
Group type: EXPERIMENTAL
Intervention: Didgeridoo lessons and daily practice at home for four months
Number of subjects: 25
Study 16377643 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for lessons)
Number of subjects: 25
Study 14645637 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days)
Number of subjects: 207
Study 14645637 — intervention group
Group type: COMPARATOR
Intervention: Inhaled oxygen placebo
Number of subjects: 207
Study 14645637 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 207
Study 10885556 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0
Study 10885556 — intervention group
Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 0
Study 9471919 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 101
Study 9471919 — intervention group
Group type: COMPARATOR
Intervention: Kirschner's wire fixation
Number of subjects: 101
Study 8509566 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg initial dose, followed by 12.5 mg 2 hours later and continuing with 12.5 mg three times daily)
Number of subjects: 81
Study 8509566 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (initial dose 20 mg followed by 20 mg three times daily)
Number of subjects: 81
Study 8509566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 3030173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid in 15 MAX-EPA capsules)
Number of subjects: 40
Study 3030173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing capsules)
Number of subjects: 40
Study 3030173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 40
Study 28941303 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft from the maxillary tuberosity (n = 30, test group)
Number of subjects: 60
Study 28941303 — intervention group
Group type: COMPARATOR
Intervention: No graft (n = 30, control group)
Number of subjects: 60
Study 26272278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch reconstruction (AP)
Number of subjects: 100
Study 26272278 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y (RY)
Number of subjects: 100
Study 24205951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/day of xylitol (5 lozenges of 1 g each, spaced throughout the day)
Number of subjects: 538
Study 24205951 — intervention group
Group type: COMPARATOR
Intervention: Sucralose placebo
Number of subjects: 538
Study 22729789 — intervention group
Group type: EXPERIMENTAL
Intervention: SS‐QoL‐12 (Stroke-Specific Quality of Life Scale)
Number of subjects: 126
Study 20479241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropocentric perspective in urban 5-year-olds
Number of subjects: 2
Study 20479241 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning in 3-year-olds
Number of subjects: 2
Study 18545176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching warm-up (DWU)
Number of subjects: 24
Study 18545176 — intervention group
Group type: COMPARATOR
Intervention: Static stretching warm-up (SWU)
Number of subjects: 24
Study 15867235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus radiotherapy
Number of subjects: 30
Study 15867235 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 30
Study 12673406 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily)
Number of subjects: 61
Study 12673406 — intervention group
Group type: COMPARATOR
Intervention: Control (no itraconazole)
Number of subjects: 61
Study 10594393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg per day in two divided doses for 1 month)
Number of subjects: 20
Study 10594393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8911886 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release fluphenazine (12 mg)
Number of subjects: 14
Study 8911886 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release fluphenazine (12 mg)
Number of subjects: 14
Study 8911886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus fluphenazine (2.5 mg)
Number of subjects: 14
Study 1530416 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 0
Study 6140022 — intervention group
Group type: EXPERIMENTAL
Intervention: Light breakfast
Number of subjects: 45
Study 6140022 — intervention group
Group type: COMPARATOR
Intervention: Fasted overnight
Number of subjects: 45
Study 31817564 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlate + NOVA intervention
Number of subjects: 0
Study 31817564 — intervention group
Group type: COMPARATOR
Intervention: MyPlate intervention
Number of subjects: 0
Study 31817564 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29924426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 266
Study 27481855 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol dosing based on total body weight
Number of subjects: 0
Study 27481855 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol dosing based on lean body weight (LBW)
Number of subjects: 0
Study 27481855 — intervention group
Group type: COMPARATOR
Intervention: Propofol pharmacodynamics (PD) measured by the bispectral index
Number of subjects: 0
Study 24398339 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1266
Study 24398339 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1266
Study 24398339 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin and Vancomycin
Number of subjects: 1266
Study 22829102 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day from cycle day 3 to 7
Number of subjects: 270
Study 22829102 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day from cycle day 3 to 7
Number of subjects: 270
Study 22829102 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 270
Study 22829102 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 270
Study 19225417 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC) by occupational physicians
Number of subjects: 240
Study 19225417 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with easy access to a psychologist
Number of subjects: 240
Study 19225417 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC)
Number of subjects: 240
Study 17599856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 U once weekly (QW)
Number of subjects: 445
Study 17599856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 U every 2 weeks (Q2W)
Number of subjects: 445
Study 17599856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 30,000 U every 3 weeks (Q3W)
Number of subjects: 445
Study 17599856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U every 4 weeks (Q4W)
Number of subjects: 445
Study 15727086 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive, ambulatory, non‐pharmacological obesity treatment programme
Number of subjects: 37
Study 15727086 — intervention group
Group type: COMPARATOR
Intervention: Control group (GK)
Number of subjects: 37
Study 12174105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formulation once daily
Number of subjects: 0
Study 12174105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formulation twice daily
Number of subjects: 0
Study 12174105 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol twice daily
Number of subjects: 0
Study 12174105 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 0
Study 9798076 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56
Study 9798076 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 56
Study 7642857 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus intravenous heparin
Number of subjects: 2972
Study 7642857 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus subcutaneous heparin
Number of subjects: 2972
Study 7642857 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue-type plasminogen activator (rt-PA) plus intravenous heparin
Number of subjects: 2972
Study 7642857 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and rt-PA plus intravenous heparin
Number of subjects: 2972
Study 7642857 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 2972
Study 7642857 — intervention group
Group type: COMPARATOR
Intervention: Shock (general outcome)
Number of subjects: 2972
Study 2614491 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 75
Study 2614491 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 75
Study 1124659 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron as ferrous carbonate once daily
Number of subjects: 27
Study 1124659 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous carbonate once daily
Number of subjects: 27
Study 1124659 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation (Control)
Number of subjects: 27
Study 30893060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)-based multimodal pain rehabilitation program (PRP)
Number of subjects: 52
Study 28931981 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 40
Study 28931981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser (LLL) acupuncture stimulation
Number of subjects: 40
Study 23490405 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy + optimal medical therapy
Number of subjects: 0
Study 23490405 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study 23288035 — intervention group
Group type: EXPERIMENTAL
Intervention: TYR-free amino acid mixture (isoleucine 15 g, leucine 22.5 g, valine 17.5 g, lysine 17.5 g, methionine 5 g, threonine 10 g, tryptophan 2.5 g)
Number of subjects: 8
Study 23288035 — intervention group
Group type: COMPARATOR
Intervention: Balanced mixture (BAL; TYR-free plus 12.5 g tyrosine and 12.5 g phenylalanine)
Number of subjects: 8
Study 21680138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-ceramic
Number of subjects: 357
Study 21680138 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-polyethylene
Number of subjects: 357
Study 18095022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (50 mg)
Number of subjects: 200
Study 18095022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16543255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg/day + Dexamethazone 2 mg/day
Number of subjects: 80
Study 16543255 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day + Placebo (folic acid tablets)
Number of subjects: 80
Study 14557016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ligation of the ascending branches of the uterine artery (Group 1, n=26)
Number of subjects: 51
Study 14557016 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative tourniquet method (Group 2, n=25)
Number of subjects: 51
Study 14557016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 10793594 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tramadol 2 mg kg‐1 (n = 9)
Number of subjects: 14
Study 10793594 — intervention group
Group type: EXPERIMENTAL
Intervention: caudal epidural tramadol 2 mg kg‐1 (n = 5)
Number of subjects: 14
Study 10793594 — intervention group
Group type: COMPARATOR
Intervention: caudal tramadol
Number of subjects: 14
Study 8614385 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX) 500 mg/m2 infused over 24 hours, three times during consolidation and every 6 weeks during maintenance
Number of subjects: 164
Study 8614385 — intervention group
Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) 20 mg/m2/week
Number of subjects: 164
Study 8614385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IV and oral MTX
Number of subjects: 164
Study 1451343 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation withdrawn at the start of the study (Group 1)
Number of subjects: 20
Study 1451343 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation continued for 12 months (Group 2)
Number of subjects: 20
Study 31996114 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal remote coaching (LRC)
Number of subjects: 3
Study 31996114 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care model (CoCM)
Number of subjects: 3
Study 31624008 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (N=104)
Number of subjects: 155
Study 31624008 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=51)
Number of subjects: 155
Study 28698881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective beta-blockers (propranolol or carvedilol) for 4 weeks
Number of subjects: 22
Study 23685085 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M No Sting Barrier Film
Number of subjects: 39
Study 23685085 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 39
Study 23685085 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 39
Study 24268395 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed foam sclerotherapy (CDFS) with 8 mL of 2% polidocanol-foam (EasyFoam) after perivenous tumescent application.
Number of subjects: 50
Study 24268395 — intervention group
Group type: COMPARATOR
Intervention: Catheter-directed foam sclerotherapy (CDFS) without pre-treatment size reduction.
Number of subjects: 50
Study 21959066 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy Group
Number of subjects: 30
Study 21959066 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study 19631847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesics
Number of subjects: 0
Study 17448944 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix vaccine
Number of subjects: 34
Study 16371866 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP.IPV
Number of subjects: 288
Study 16371866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 288
Study 11695207 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 110
Study 11695207 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Fresh Stripe Toothpaste
Number of subjects: 110
Study 11695207 — intervention group
Group type: COMPARATOR
Intervention: Placebo Toothpaste
Number of subjects: 110
Study 9885411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% all-trans-retinoic acid (RA) cream
Number of subjects: 0
Study 9885411 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% salicylic acid (SA) in nonionic oil-in-water emulsions
Number of subjects: 0
Study 9885411 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated emulsion (control)
Number of subjects: 0
Study 9885411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RA or SA with sodium lauryl sulfate (SLS)
Number of subjects: 0
Study 7617817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ACTH
Number of subjects: 16
Study 7617817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1975483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine during saline infusion
Number of subjects: 9
Study 1975483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine during esmolol infusion
Number of subjects: 9
Study 1975483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine containing 5, 10, or 15 micrograms of epinephrine after propranolol injection
Number of subjects: 9